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Abstract Vav functions as a specific GDP/GTP nucleotide
exchange factor which is regulated by tyrosine phosphorylation
in the hematopoietic system. Loss of the amino-terminus
sequences of Vav was sufficient to control its transforming
potential and its function in T cells. We report here the
identification of the hematopoietic GDP dissociation inhibitor
protein, Ly-GDI, as a protein that interacts with the amino-
terminus of Vav. Further analysis confirmed that Vav and Ly-
GDI interact both in in vitro and in in vivo assays. This
association is maximal only when the amino region of Vav is
intact and requires an intact carboxy-terminus of Ly-GDI. The
interaction between Vav and Ly-GDI is not dependent on the
tyrosine phosphorylation status of Vav. In addition, Rho-GDI,
the highly homologous protein to Ly-GDI, associates with Vav as
well. The contribution of the interaction between Vav and GDIs,
proteins that are involved in the GDP/GTP exchange processes,
to the biological function of Vav is further discussed.
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1. Introduction
Although the vav proto-oncogene (Vav) was initially iden-
ti¢ed as an oncogene, accumulating results from the past sev-
eral years have placed the molecule as an important signal
transducer protein, functioning at a pivotal role in hemato-
poietic cell activation [1^4]. Thus, Vav functions as a speci¢c
GDP/GTP nucleotide exchange factor which is regulated by
tyrosine phosphorylation in hematopoietic cells, where it is
exclusively expressed. [1,2,5^8]. These signaling cascades
evoke numerous responses such as capping of the T cell re-
ceptor (TCR) following its activation, receptor recruitment of
the actin cytoskeleton to the CD3 j chain of the TCR, inter-
leukin-2 production and proliferation, cell cycle progression,
activity of nuclear factor of activated T cells (NF-AT), phos-
phorylation of SLP-76 and Ca2 mobilization [3,4]. Thus, in T
cells, Vav integrates signals from lymphocyte antigen recep-
tors and costimulatory receptors to control development, dif-
ferentiation and cell cycle.
Vav encodes a unique protein (95 kDa) that contains a
collection of several modular motifs characteristic of tyrosine
signal transducer proteins, such as a dbl homology domain
(DH) that activates GTP-bound proteins of the Rho-like fam-
ily of proteins [9^11]; a pleckstrin homology domain [12]; a
Src homology 2 (SH2) and two Src homology 3 (SH3) do-
mains [13,14]. Additional regions that can be found in Vav are
a proline rich motif that might allow it to bind to SH3-con-
taining proteins [1] and an acidic rich region [1]. The leucine
rich amino-terminus of Vav is similar to the ‘calponin homol-
ogy’ (CH) region (residues 3^115) which functions as an actin-
binding protein domain in other proteins [15].
The mechanism by which vav transforms ¢broblasts is still
poorly understood [1,16,17]. Nucleotide sequence analysis of
the vav oncogene revealed that it was activated in vitro by
replacement of 67 residues of its amino-terminus with sequen-
ces of pSV2neo, co-transfected as a selectable marker [1]. Vav
produces minimal transformation of NIH3T3 murine ¢bro-
blasts only when the protein is grossly overexpressed [16,17].
By contrast, removal of its amino-terminus sequences (65 res-
idues), mimicking its original mode of activation, is su⁄cient
to induce vav transformation [16,17]. This sequence controls
not only vav transformation but also its function in T cells.
Thus, unlike Vav, the truncated oncogenic protein does not
cause any changes in NF-AT transcription [18]. Truncation of
the amino-terminus of another member of the Vav family of
signaling proteins, vav2, also renders it a transforming gene
[19]. Hence, Vav probably interacts through its amino-termi-
nus with a regulatory protein which controls both its activity
as an oncogene and its function in the proximal TCR signal-
ing pathways.
Indeed, protein^protein interactions were shown to play an
important role in the regulation of Vav activity. Thus, muta-
tions of the SH2 and SH3 domains of vav were found to
impair the transforming activity of the protein and its ability
to associate with several proteins [20,21]. Two proteins were
reported to associate with the amino-terminus of Vav: Socs1,
a downstream component of the Kit receptor tyrosine kinase
signaling pathway [22], and ENX-1, a putative transcriptional
regulator of homeobox gene expression [23]. However, the
contribution of these proteins to the function of Vav is still
not known [22,23].
Our attempts to isolate additional proteins that associate
with the amino-terminus of Vav by the use of the yeast two
hybrid system [24] led us to the isolation of a Vav-binding
protein, the GDP dissociation inhibitor protein, Ly-GDI
[25,26]. Our results show that an intact amino-terminus of
Vav is needed to allow interaction between these two proteins
and may explain why an intact amino-terminus of Vav is
critical for its activity in oncogenic, mitogenic and signaling
events.
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2. Materials and methods
2.1. Plasmids
The fragments used for generation of the plasmids (see below) used
in this study were obtained by PCR ampli¢cation with primers that
carry restriction sites for subcloning purposes (underlined). The PCR
products were sequenced prior to their use for subcloning.
2.1.1. Yeast two hybrid plasmids. VavY2H1ÿ178 carries residues 1^
178 of Vav and was created by humN1-5P-CCGGGGAATTCGC-
CCTGGGCAGGGTAGCC and humN2-5P-GGCCCCGGATCC-
GCGCATCAGGTCCTCATA. The PCR product was subcloned be-
tween the EcoRI and BamHI sites of pBTM116. Additional plasmids
that were used are pGAD1318 as well as pGAD1318 that carries
Lamin (pLex-Lamin).
2.1.2. pGEX-2TK (GST) expression plasmids. (1) GST-Ly carries
the entire coding region of Ly-GDI and was prepared by LyGDIF-5P-
CCGGGGGGATCCATGACTGAAAAAGCCCCA and LyGDIR-
5P-GGCCCCGAATTCATGCATTCATTCTGTCCA. (2) GST-LyN
carries the amino-terminus of Ly-GDI (residues 1^59) and was gen-
erated by Ly-GDIF and Ly60R-5P-CCGGGGAATTCAGGACCA-
TCTCCCAGCAG. (3) GST-LyC carries the carboxy Ly-GDI (resi-
dues 60^201) and was prepared by Ly61F-5P-CCCGGATCCCTG-
CTGGGAGATGGTCCT and Ly-GDIR. (4) GSTVav1ÿ178 carries
residues 1^178 of Vav and was ampli¢ed with: GST178F-5P-CC-
GGGGGGATCCGCCCTGGGCAGGGTAGCC and GST178R-5P-
GGCCCCGAATTCGCGCATGAGGTCCTCATA. (5) GSTRho-
GDI was created by GSTRho-GDIF-5P-CCGGGGGGATCCAG-
CATGGCTGAGCAGGAG and GSTRho-GDIR-5P-GGCCCCGA-
ATTCTCAGTCCTTCCAGTCCTT. The PCR products were di-
gested with BamHI and EcoRI restriction enzymes (underlined
above) and subcloned into the glutathione-S-transferase (GST) fusion
protein vector, pGEX-2TK.
2.1.3. Mammalian expression vectors. Vav and Ly-GDI were sub-
cloned at the BamHI and EcoRI sites of the mammalian expression
vector driven by the CMV promoter, pCDNA3, thus creating
pcDNA3-Vav and pcDNA3-Ly, respectively.
2.2. Cell culture
Cell lines used in this study are: NIH3T3 murine ¢broblasts,
NIH3T3 cells that express the vav oncogene (NIH/vav) [1], NIH3T3
cells that express Vav (NIH/proto-vav) [16]. These cell lines were
grown in Dulbecco’s modi¢ed Eagle’s medium (DMEM) containing
10% calf serum. Jurkat T cells were grown in RPMI medium contain-
ing 10% fetal calf serum (FCS) and 293T cells were grown in DMEM
containing 10% FCS.
2.3. Gene transfer assays
1U106 293T cells were transiently transfected with 10 Wg DNA of
various plasmids (see Section 3) by using the calcium phosphate meth-
od. The e⁄ciency of transfection was con¢rmed by the £uorescence of
the green £uorescence plasmid included in the transfection. Cells were
washed 12 h following transfection and were harvested 48 h past
transfection.
2.4. Immunoprecipitation and immunoblotting
Cells lysis, immunoprecipitation and immunoblotting were per-
formed as previously described [15,16,20,21,27].
2.5. Immobilization of bacterial fusion proteins on glutathione
Sepharose beads
Fusion proteins were puri¢ed from transformed Escherichia coli
bacteria and bound to glutathione Sepharose beads (Pharmacia) as
previously described [20,21,27].
2.6. Activation of Jurkat T cells
Jurkat T cells at 2U107 cells/100 Wl were activated with anti-CD3A
monoclonal antibody (Ab) OKT3 (1:100; American Type Tissue Cul-
ture Collection) for 1 min at 37‡C.
2.7. Abs
Anti-Vav Abs were raised in rabbits against a speci¢c peptide
of vav, residues 528^541 [16]; anti-phosphotyrosine (Ptyr), 4G10
(UBI); anti-CD3 (American Type Tissue Culture Collection);
monoclonal anti-Vav used in Western blots (UBI); and anti-Ly-
GDI (UBI).
2.8. Yeast two hybrid system
The Saccharomyces cerevisiae L40 cells (MATa trp1 leu2 his3 LY-
S: :lexA-HIS3 URA3: :lexA-lacZ) were grown in YPD medium (1%
yeast extract, 2% polypeptone, 2% glucose) at 30‡C. L40 cells were co-
transformed sequentially by the lithium acetate method with
VavY2H1ÿ178 and with a cDNA library from Jurkat cells fused to
the GAL4 activation domain in pGAD1318 (kindly given to us by
J. Camonis). Double transformants were plated on yeast medium
lacking Trp, Leu and His (3LWH) and containing 50 mM 3-ami-
no-1,2,4-triazole (3AT; Sigma) to prevent background growth. After
5 days at 30‡C, colonies were patched on the same medium and
replica plated for L-galactosidase activity. To rescue the binding plas-
mids, HB101 bacterial cells were transformed with DNA from pos-
itive clones. The transformed cells were grown in M9 minimal medium
supplemented with the appropriate amino acids. To ensure that each
colony incorporated only one plasmid, DNA was prepared from col-
onies of HB101 cells and was subjected to PCR ampli¢cation. To
obtain a better quality as well as quantity of the DNA from the
positive clones, the chosen plasmids were introduced into DH5K cells
from which DNA was prepared. To test the speci¢city of binding of
the rescued plasmids, we retransformed L40 cells with the appropriate
Vav plasmid or with pLex-Lamin. Sequences of cDNA inserts from
positive clones were performed by the chain termination dideoxy se-
quencing method and analyzed by the FASTA program.
3. Results
To identify proteins that associate with the amino-terminus
region of Vav and are important for its activity as a signal
transducer and transforming protein, we used the yeast two
hybrid system [24]. As a bait, we chose the amino 178 residues
(VavY2H1ÿ178) which contain the CH domain (residues 3^
115) as well as the acidic region (residues 132^176). Yeast
L40 cells were co-transformed with VavY2H1ÿ178 and a hu-
man cDNA of Jurkat T cells hooked to pGAD1318 that car-
ries the activating domain of GAL4. Fifty clones grew on
3LWH medium that contains 50 mM 3AT. These clones
also produced L-galactosidase, thus indicating that the bait
interacted with a protein encoded by the expression library.
The positive interactor plasmids were segregated from the bait
plasmid following the procedure detailed in Section 2, and
several of them were eliminated as they interacted non-specif-
ically with the control plasmid (Lamin). One of the proteins
that bound to the VavY2H1ÿ178 bait, interactor (112), showed
a 100% identity to an already known human protein, Ly-GDI,
a 28 kDa protein, that has striking homology to the product
of a previously cloned gene, Rho-GDI [25,26]. These proteins
were shown to inhibit GDP/GTP exchange on the Rho family
of GTPases [25,26,28]. Unlike Rho-GDI, Ly-GDI is expressed
only in hematopoietic tissues and predominantly in B and T
lymphocyte cell lines [25,26]. It is noteworthy that none of the
isolated proteins under the stringent conditions that we used
corresponded to ENX-1 or hSoc1.
To assess the nature of the association between Vav and
Ly-GDI, we employed the highly sensitive GST in vitro bind-
ing assay (Fig. 1A, upper panel). Vav from NIH/proto-vav
cells was found to associate speci¢cally with Ly-GDI ex-
pressed as a GST bacterial fusion protein (GST-Ly; lane 4),
but not with GST (lane 3). No binding to GST or GST-Ly
from NIH3T3 cells could be observed (lanes 5 and 6). The
ratio of bound Vav protein to GST-Ly (lane 4) versus the
amount of Vav present in the cells, as determined by immu-
noprecipitation with anti-Vav Abs (lane 2), indicates that a
substantial amount of Vav binds to Ly-GDI. Similar results
were obtained when the blot was rehybridized with anti-Ptyr
Abs (Fig. 1A, lower panel).
FEBS 23268 28-1-00
M. Groysman et al./FEBS Letters 467 (2000) 75^8076
Since yeast cells co-transformed with either the oncogenic
vav region (vavY2H1ÿ45) or the amino residues 1^93 of Vav
(Vav2H1ÿ93) together with Ly-GDI grew on 3LW plates, but
failed to grow on 3WLH plates (data not shown), we con-
cluded that the amino acid residues critical for vav transfor-
mation do not directly bind to Ly-GDI. We then tested
whether Ly-GDI associates with the product of the vav onco-
gene (87 kDa) which lacks the amino 67 residues that do not
associate with Ly-GDI (see above), but retains the rest of the
protein. A similar experiment to the one described in Fig. 1A
was performed, except NIH/vav cells were used (Fig. 1B,
upper panel). Only a tiny fraction of the truncated/transform-
ing form of Vav present in the cells, as evaluated by immu-
noprecipitation (lane 2), bound to GST-Ly (lane 4). More-
over, the use of anti-Ptyr Abs illustrated that there is no
tyrosine-phosphorylated vav protein associated with GST-
Ly, probably due to the low level of bound protein (Fig.
1B, lower panel). The fact that the vav sequences critical for
transformation do not associate with Ly-GDI (yeast two hy-
brid, data not shown) and the truncated/transforming vav
protein (which retains residues 68^845) hardly associates
with Ly-GDI (Fig. 1B) strongly suggest that an intact ami-
no-terminus of Vav is needed for its e⁄cient binding to Ly-
GDI.
We then measured the binding of Ly-GDI to the amino
region of Vav (residues 1^178) expressed as a GST bacterial
fusion protein (GSTVav1ÿ178 ; Fig. 2). Ly-GDI from Jurkat T
cells associates with GSTVav1ÿ178 (lane 2), but not with GST
(lane 1). The relatively small fraction of Ly-GDI bound to
GSTVav1ÿ178 compared to its level in the cells (lane 2 vs.
lane 3) probably re£ects an improper folding of the amino-
terminus region of Vav when expressed as a GST fusion pro-
tein. No binding of Ly-GDI could be demonstrated to either
GSTVav1ÿ93 or GSTVav66ÿ178 (data not shown), thus con-
Fig. 2. The product of Ly-GDI associates with Vav. Lysates of Jur-
kat cells were either incubated with GST (lane 1) and GSTVav1ÿ178
(lane 2) bacterial fusion proteins immobilized on glutathione Seph-
arose beads or loaded unbound on a SDS^PAGE (lane 3). The pro-
teins were resolved on SDS^PAGE and immunoblotted with anti-
Ly-GDI. The arrow indicates the position of the product of Ly-
GDI (28 kDa).
Fig. 3. Vav associates with Ly-GDI in the cells. (A) Lysates of
293T cells that were transfected with either Ly-GDI (293T+Ly; lane
2) or Ly-GDI and Vav (293T+Ly+Vav; lane 3) were immunopre-
cipitated with anti-Ly-GDI Abs. The immunoprecipitated proteins
and lysates of Jurkat T cells (lane 1) were resolved on SDS^PAGE,
immunoblotted with anti-Vav Abs (upper panel) and then rehybrid-
ized with anti-Ly-GDI Abs (lower panel). (B) Lysates of NIH3T3
(lane 1) and Jurkat T cells (lanes 2 and 3) were immunoprecipitated
with anti-Vav Abs (Vav; lanes 1 and 2) or anti-Ly-GDI Abs (Ly;
lane 3). The immunoprecipitated proteins and lysates of Jurkat cells
(lane 4) were resolved on SDS^PAGE, immunoblotted with anti-
Vav Abs (upper panel) and then rehybridized with anti-Ly-GDI
Abs (lower panel). The arrows indicate the positions of the product
of Vav (95 kDa) and Ly-GDI (28 kDa).
Fig. 1. Association of Vav (A) and the product of the vav oncogene (B) with Ly-GDI. (A) Lysates of NIH/proto-vav were immunoprecipitated
with either preimmune sera (P.I. ; lane 1) or anti-Vav Abs (I; lane 2). In addition, bacterial fusion proteins that express GST (lanes 3 and 5)
and Ly-GDI (GST-Ly; lanes 4 and 6) were immobilized on glutathione Sepharose beads and incubated with lysates of NIH/proto-vav cells
(lanes 3 and 4) and NIH3T3 (lanes 5 and 6). The bound proteins were resolved on sodium dodecyl sulfate^polyacrylamide gel electrophoresis
(SDS^PAGE), immunoblotted with anti-Vav Abs (upper panel) and rehybridized with anti-Ptyr Abs (lower panel). The arrow indicates the po-
sition of the product of Vav (95 kDa). (B) A similar experiment to the one described in (A) was performed, except lysates of NIH/vav cells
were used instead of lysates of NIH/proto-vav. The arrow indicates the position of the product of the vav oncogene (87 kDa).
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¢rming that an intact amino-terminus of Vav is needed for
maximal binding to Ly-GDI.
We next tested whether the interaction between Vav and
Ly-GDI also occurs in the cells (Fig. 3A). Only when 293T
cells were transiently transfected with both Vav and Ly-GDI,
anti-Ly-GDI Abs co-immunoprecipitated the Vav protein
(Fig. 3A, upper panel, lane 3). However, when 293T cells ex-
pressed Ly-GDI only (Fig. 3A, lower panel), Vav could not be
detected (Fig. 3A, upper panel, lane 2). These results clearly
illustrate that the interaction between Ly-GDI and Vav is
most likely to occur in vivo. These results were further vali-
dated when a similar experiment was performed with Jurkat T
cells, in which Ly-GDI and Vav are both physiologically ex-
pressed (Fig. 3B). Thus, Vav could be detected when lysates of
Jurkat T cells were immunoprecipitated with anti-Ly-GDI
Abs (Fig. 3B, upper panel, lane 3) and respectively Ly-GDI
is present when lysates of Jurkat T cells were immunoprecipi-
tated with anti-Vav Abs (Fig. 3B, lower panel, lane 2). Again,
the interaction between Vav and Ly-GDI is distinctly demon-
strated in the cells.
It was previously demonstrated that in Jurkat T cells, stim-
ulation of the TCR by crosslinking with anti-CD3 (OKT3)
monoclonal Abs increases tyrosine phosphorylation of a num-
ber of proteins, including Vav [5,6]. We therefore analyzed
whether Vav from OKT3-stimulated Jurkat T cells will asso-
ciate preferentially to Ly-GDI (Fig. 4). Our experiments
clearly demonstrate that an equal amount of Vav from acti-
vated (+; Fig. 4A, lane 6) or non-activated (3 ; Fig. 4A, lane
5) T cells associates to GST-Ly, despite the fact that an in-
crease in tyrosine phosphorylation of Vav could be observed
(Fig. 4B, lane 3 vs. lane 2). Thus, the association between Vav
and Ly-GDI does not depend on the tyrosine phosphorylation
status of Vav.
The cDNA encoding Ly-GDI that we have isolated through
our yeast two hybrid screen contained the entire coding region
of the protein (data not shown). Although the structure of Ly-
GDI is not yet resolved, the fact that it is highly homologous
to Rho-GDI suggests that its structure will be similar. Rho-
GDI is composed of two structurally distinct regions of the
protein. One is the N-terminal region (residues 1^60) that is
£exible and unstructured in solution and is required for inhi-
bition of nucleotide dissociation from Cdc42. The second re-
gion is the carboxy-terminus (residues 59^204) that is similar
to the structure of an immunoglobulin and is involved in
binding to the Rho family member Cdc42, yet it does not
a¡ect the rate of nucleotide dissociation from the GTPase
[29,30]. We next wished to establish the requirements for bind-
ing of Vav to Ly-GDI (Fig. 5). Our results show that the
interaction of Vav with either the region in Ly-GDI that is
homologous to the £exible N-terminal arm of Rho-GDI (1^
59; GST-LyN) or with the immunoglobulin-like domain (res-
idues 60^201; GST-LyC) is reduced (lanes 3 and 4), compared
to its binding to the intact Ly-GDI protein (lane 2). These
results imply that the entire Ly-GDI is needed for maximal
association with Vav. However, the putative immunoglobulin-
Fig. 5. An intact Ly-GDI exhibits maximal binding to Vav. Lysates
of NIH/proto-vav were incubated with GST (lane 1), GST-Ly (lane
2), GST-LyN (lane 3) or GST-LyC (lane 4) immobilized on gluta-
thione Sepharose beads. The bound proteins were resolved on SDS^
PAGE and immunoblotted with anti-Vav Abs. The arrow indicates
the position of the product of Vav (95 kDa).
Fig. 6. Association of Rho-GDI with Vav and the product of the
vav oncogene. Lysates of NIH3T3 (lanes 1, 4 and 5), NIH/vav
(lanes 2, 6 and 7) and NIH/proto-vav (lanes 3, 8 and 9) were either
immunoprecipitated with anti-Vav Abs (I; lanes 1^3) or bound to
either GST (lanes 4, 6 and 8) or GSTRho (lanes 5, 7 and 9). The
bound/immunoprecipitated proteins were resolved on SDS^PAGE,
immunoblotted with anti-Vav Abs (upper panel) and rehybridized
with anti-Ptyr Abs (lower panel). The arrows indicate the positions
of Vav (95 kDa) and the product of the vav oncogene (87 kDa).
Fig. 4. The association between Vav and Ly-GDI is not dependent
on stimulation of the TCR. Lysates of Jurkat T cells that were ei-
ther OKT3-activated (+) or non-activated (3) were immunoprecipi-
tated with preimmune sera (P.I.; lane 1) or anti-Vav Abs (I; lanes 2
and 3). In addition, lysates of Jurkat T cells either non-activated or
OKT3-activated were bound to GST (lanes 4 and 5) or GST-Ly
(lanes 6 and 7). The bound/immunoprecipitated proteins were re-
solved on SDS^PAGE, immunoblotted with anti-Vav Abs (A) and
rehybridized with anti-Ptyr Abs (B). The arrow indicates the posi-
tion of the product of Vav (95 kDa).
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like domain exhibits substantial binding to Vav (lane 3) as
compared to the binding properties of the presumed £exible
N-terminal arm (lane 4).
Taking into account that the highest homology between Ly-
GDI and Rho-GDI is at their carboxy region, which is critical
for Ly-GDI interaction with Vav (Fig. 5), and that both GDIs
are expressed in Jurkat T cells, we tested whether Rho-GDI
associates with Vav (Fig. 6). Our results clearly illustrate that
a substantial amount of Vav present in NIH/proto-vav cells
(Fig. 6A, lane 3) binds to Rho-GDI when expressed as a GST
fusion protein (GSTRho; Fig. 6A, lane 9). This is also veri¢ed
by the use of anti-Ptyr Abs (Fig. 6B). Moreover, only a min-
ute amount of the truncated/oncogenic vav (87 kDa) which
could solely be observed after longer exposures of the blot
(data not shown and Fig. 6, lane 7) associates with Rho-
GDI, despite the fact that this protein is highly expressed in
NIH/vav (Fig. 6, lane 2).
4. Discussion
We report here the identi¢cation of Ly-GDI as a protein
that until recently was an elusive partner of the region of Vav
(amino-terminus) that is critical for its activity as a transform-
ing and signal transducing protein. Vav (95 kDa) from Jurkat
T cells (where it is exclusively expressed) and from NIH3T3
cells (where it is ectopically expressed) interacts with Ly-GDI
both in vitro and in vivo (Figs. 1^5). By contrast, the trans-
forming protein of vav (87 kDa) which lacks part of its amino-
terminus hardly associates with Ly-GDI (Fig. 1B). These re-
sults correlate with the observation that removal of 127, 168
or 186 residues of the amino-terminus of Vav produces a
protein that transforms even more potently than the oncogene
that we originally isolated [31,32]. The loss of binding that
follows amino-terminal truncation or replacement by
pSV2neo-derived residues does not imply that this region di-
rectly interacts with Ly-GDI (data not shown), but rather
suggests that the amino-terminal region of Vav is involved
in protein folding and is required for maximal binding of
Vav to Ly-GDI.
The question then arises whether additional proteins that
bind to Vav are also critical for its biological activity. Trun-
cation of 65 amino acids at the amino-terminus of Vav dis-
rupts the putative actin-binding, CH domain (residues 3^115).
Nonetheless, the direct association of Vav with actin through
this region has been disputed by Gimona and Winder [33]. In
addition, ENX-1 that was reported to associate with the ami-
no-terminus of Vav associates with residues 66^172 of Vav,
but not with the region of Vav that is critical for its trans-
forming activity (residues 1^65) [23]. Hence, the association
between Vav and ENX-1 may be important for the function
of Vav as a signal transducer protein, but is not critical for
vav transformation.
The fact that Vav binds also to Rho-GDI (which unlike Ly-
GDI is expressed in ¢broblasts) suggests that this interaction
might be su⁄cient to block Vav transformation, unless its
amino-terminus is truncated, and its association with Rho-
GDI is disrupted (Fig. 6). Indeed, transformation of
NIH3T3 cells by the vav proto-oncogene was blocked when
Ly-GDI was added in excess, whereas no di¡erences in the
transforming potential were exhibited when the vav oncogene
was used under similar conditions (Groysman et al., unpub-
lished data). In hematopoietic cells, where both GDI proteins
(Ly-GDI and Rho-GDI) interact with Vav, more than one
GTP-binding protein might be a¡ected. Several studies indi-
cate that Ly-GDI and Rho-GDI might not simply represent
redundant proteins, but they probably have more complex
and distinctive activities. For instance, knock-out of Ly-
GDI in mice leads only to a slight reduction in the capacity
of macrophages lacking Ly-GDI to generate superoxide and
has no e¡ect on lymphoid or hematopoietic development
[34,35]. By contrast, knock-out of Rho-GDI leads to progres-
sive impairment of kidneys and reproductive organs [36]. In
addition, although Rho-GDI and Ly-GDI can associate with
the same Rho proteins (RhoA, Cdc42H and Rac1) in vitro,
these proteins are in vivo partners of Rho-GDI but not of Ly-
GDI [37]. Loss of the ability of the truncated Vav protein to
stimulate NF-AT activity in T cells [18] is most probably the
result of its inability to interact with GDI proteins, an inter-
action that is most likely required for the proper function of
Vav in T cells.
How then could the interaction between Vav and GDI pro-
teins control the biological activity of Vav? Vav stimulates the
exchange of GDP to GTP (‘on’) of GTP-binding proteins
such as Rho, Rac and Cdc42H [7,8]. This activity is tightly
regulated by its tyrosine phosphorylation status. However, the
transforming vav protein that lacks the Ly-GDI-binding re-
gion is constitutively active without being regulated by tyro-
sine signaling cascades [7,8]. On the other hand, the GDIs
were shown to inhibit the dissociation of GDP from members
of the Rho proteins, thus keeping the GTP-binding proteins in
a non-active form (‘o¡’) [25,26,28,38]. Rho-GDI was shown
to strongly prevent the exchange factors from activating the
Rho proteins by interacting with its substrate, unless their
association is disturbed by proteins such as ezrin/radixin/moe-
sin proteins (ERM) [39,40] or Merilin [41]. We envision that
Vav competes with proteins such as ERM for their binding to
GDI proteins, thus preventing GDI from interacting with its
substrate and permitting the exchange of GDP to GTP (‘on’)
by the DH domain. Alternatively, GDIs could serve as chap-
erone-like proteins that translocate GTP-binding proteins
through the cytosol to their membrane site of action. Loss
of the association of oncogenic vav with GDIs might enhance
its binding to the membrane fraction, where it can be more
active as a GDP/GTP exchange factor. This e¡ect may help to
explain the results of Abe et al. [32] who concluded that the
amino-terminus deletion of Vav led to its enhanced associa-
tion with the membrane-containing particulate fraction.
Which of these hypotheses indeed re£ects the intricate situa-
tion in vivo remains to be established experimentally. None-
theless, the association between Vav and GDIs (Ly-GDI and
Rho-GDI) likely regulates the activity of Vav as an exchange
factor.
In conclusion, Vav and Ly-GDI are proteins that are ex-
clusively expressed in hematopoietic cells. Both are involved in
the GDP/GTP exchange processes, one as an exchange factor
(Vav) and the other as a dissociation inhibitor factor (Ly-
GDI). Moreover, Vav associates with the ubiquitously ex-
pressed Rho-GDI. Our results imply that the interaction be-
tween Vav and GDIs contributes an additional regulatory
step to the role of Vav in signaling cascades following activa-
tion of hematopoietic cells and probably also to its function as
an oncogene.
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